NASDAQ: CDMO | Healthcare / Biotechnology / USA |
5.08 | +0.2300 | +4.74% | Vol 1.84M | 1Y Perf -67.05% |
Nov 29th, 2023 16:00 DELAYED |
BID | 4.80 | ASK | 7.06 | ||
Open | 4.96 | Previous Close | 4.85 | ||
Pre-Market | - | After-Market | 5.02 | ||
- - | -0.06 -1.18% |
Target Price | 22.33 | Analyst Rating | Moderate Buy 1.75 | |
Potential % | 339.57 | Finscreener Ranking | ★★★★★ 59.32 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★★+ 57.56 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★★★ 77.74 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 2.92 | Earnings Rating | Strong Sell | |
Market Cap | 320.61M | Earnings Date | 5th Dec 2023 | |
Alpha | 0.00 | Standard Deviation | 0.18 | |
Beta | 1.72 |
Today's Price Range 4.845.16 | 52W Range 4.6021.05 | 5 Year PE Ratio Range -18.80862.80 |
Summary:
Sell
Technical Indicators: | Sell |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | -6.62% | ||
1 Month | -17.13% | ||
3 Months | -57.67% | ||
6 Months | -66.18% | ||
1 Year | -67.05% | ||
3 Years | -44.30% | ||
5 Years | -4.15% | ||
10 Years | -47.03% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -8.09 | |||
ROE last 12 Months | 105.16 | |||
ROA (5Y Avg) | -1.82 | |||
ROA last 12 Months | 33.79 | |||
ROC (5Y Avg) | -16.68 | |||
ROC last 12 Months | 40.18 | |||
Return on invested Capital Q | -0.20 | |||
Return on invested Capital Y | 46.76 | |||
Assets Turnover | 0.40 | |||
Receivables Turnover | 5.60 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
8.70 | ||||
5.05 | ||||
6.79 | ||||
92.10 | ||||
-10.30 | ||||
-0.04 | ||||
5.05 | ||||
2.91 | ||||
1.02B | ||||
Forward PE | 27.44 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.30 | ||||
1.80 | ||||
0.50 | ||||
1.00 | ||||
1.70 | ||||
Leverage Ratio | 2.70 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
21.90 | ||||
3.20 | ||||
7.60 | ||||
-8.50 | ||||
84.17 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
134.18M | ||||
2.15 | ||||
26.89 | ||||
10.78 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q01 2024 | -0.04 | -0.03 | 25.00 |
Q04 2023 | -0.02 | 0.00 | 100.00 |
Q03 2023 | -0.08 | 0.03 | 137.50 |
Q02 2023 | -0.05 | -0.04 | 20.00 |
Q01 2023 | 0.03 | 0.02 | -33.33 |
Q04 2022 | -0.02 | 0.04 | 300.00 |
Q03 2022 | 0.05 | 0.06 | 20.00 |
Q02 2022 | -0.01 | 0.07 | 800.00 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
10/2023 QR | -0.09 | -28.57 | Negative |
1/2024 QR | -0.04 | -500.00 | Negative |
4/2024 FY | -0.04 | 55.56 | Positive |
4/2025 FY | 0.20 | 0.00 | - |
Next Report Date | 5th Dec 2023 |
Estimated EPS Next Report | -0.09 |
Estimates Count | 1 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 1.84M |
Shares Outstanding | 63.11K |
Shares Float | 61.60M |
Trades Count | 13.89K |
Dollar Volume | 9.29M |
Avg. Volume | 837.67K |
Avg. Weekly Volume | 1.00M |
Avg. Monthly Volume | 809.27K |
Avg. Quarterly Volume | 700.09K |
Avid Bioservices Inc. (NASDAQ: CDMO) stock closed at 5.08 per share at the end of the most recent trading day (a 4.74% change compared to the prior day closing price) with a volume of 1.84M shares and market capitalization of 320.61M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 227 people. Avid Bioservices Inc. CEO is Nicholas S. Green.
The one-year performance of Avid Bioservices Inc. stock is -67.05%, while year-to-date (YTD) performance is -63.11%. CDMO stock has a five-year performance of -4.15%. Its 52-week range is between 4.6 and 21.05, which gives CDMO stock a 52-week price range ratio of 2.92%
Avid Bioservices Inc. currently has a PE ratio of 8.70, a price-to-book (PB) ratio of 5.05, a price-to-sale (PS) ratio of 6.79, a price to cashflow ratio of 92.10, a PEG ratio of -, a ROA of 33.79%, a ROC of 40.18% and a ROE of 105.16%. The company’s profit margin is 84.17%, its EBITDA margin is 7.60%, and its revenue ttm is $134.18 Million , which makes it $2.15 revenue per share.
Of the last four earnings reports from Avid Bioservices Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.09 for the next earnings report. Avid Bioservices Inc.’s next earnings report date is 05th Dec 2023.
The consensus rating of Wall Street analysts for Avid Bioservices Inc. is Moderate Buy (1.75), with a target price of $22.33, which is +339.57% compared to the current price. The earnings rating for Avid Bioservices Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Avid Bioservices Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Avid Bioservices Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 20.57, ATR14 : 0.43, CCI20 : -92.45, Chaikin Money Flow : -0.10, MACD : -0.64, Money Flow Index : 42.74, ROC : -3.79, RSI : 34.65, STOCH (14,3) : 33.33, STOCH RSI : 0.75, UO : 36.80, Williams %R : -66.67), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Avid Bioservices Inc. in the last 12-months were: Carleone Joseph (Buy at a value of $190 600), Daniel P. Hart (Sold 0 shares of value $0 ), Daniel P. Hart (Sold 8 924 shares of value $106 195 ), Daniel Ryan Hart (Option Excercise at a value of $11 320), Daniel Ryan Hart (Sold 7 779 shares of value $141 987 ), Esther Alegria (Sold 5 321 shares of value $86 856 ), Green Nicholas (Sold 0 shares of value $0 ), Green Nicholas (Sold 63 554 shares of value $932 716 ), Green Nicholas Stewart (Sold 40 856 shares of value $518 928 ), Gregory P. Sargen (Sold 7 011 shares of value $141 919 ), Hancock Richard B (Option Exercise at a value of $54), Hancock Richard B (Sold 5 000 shares of value $81 838 ), Hart Daniel R (Sold 6 884 shares of value $87 436 ), Jeanne Thoma (Option Excercise at a value of $0), Kwietniak Matthew R. (Sold 3 947 shares of value $50 128 ), Mark R. Ziebell (Option Excercise at a value of $0), Mark R. Ziebell (Sold 1 886 shares of value $31 177 ), Matthew R. Kwietniak (Sold 0 shares of value $0 ), Matthew R. Kwietniak (Sold 5 172 shares of value $61 394 ), Nicholas S. Green (Option Excercise at a value of $0), Nicholas S. Green (Sold 15 698 shares of value $267 391 ), Richard A. Richieri (Sold 0 shares of value $0 ), Richard A. Richieri (Sold 3 764 shares of value $44 282 ), Richard B. Hancock (Option Excercise at a value of $150 766), Richard B. Hancock (Sold 40 000 shares of value $667 898 ), Richieri Richard A. (Sold 2 758 shares of value $35 030 ), Ziebell Mark (Sold 0 shares of value $-246 750 ), Ziebell Mark (Sold 31 684 shares of value $536 881 ), Ziebell Mark R (Sold 3 657 shares of value $47 458 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Moderate Buy | Strong Buy |
Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on development and current Good Manufacturing Practices (cGMP) of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.
CEO: Nicholas S. Green
Telephone: +1 714 508-6100
Address: 2642 Michelle Drive, Tustin 92780, CA, US
Number of employees: 227
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.